Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
髓系白血病
医学
癌症研究
作者
Andreas Hochhaus,Jianxiang Wang,Dong‐Wook Kim,Dennis Dong Hwan Kim,Jiřı́ Mayer,Yeow‐Tee Goh,Philipp le Coutre,Naoto Takahashi,In Ho Kim,Gabriel Étienne,David Andorsky,Ghayas C. Issa,Richard A. Larson,Felice Bombaci,S. S. Kapoor,Tracey McCulloch,Kamel Malek,Lillian Yau,Sophie Ifrah,Matthias Hoch
Patients with newly diagnosed chronic myeloid leukemia (CML) need long-term therapy with high efficacy and safety. Asciminib, a BCR::ABL1 inhibitor specifically targeting the ABL myristoyl pocket, may offer better efficacy and safety and fewer side effects than currently available frontline ATP-competitive tyrosine kinase inhibitors (TKIs).